Fanconi Anemia Panel

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy Genes Gene CPT Codes Copy CPT Codes
10361 BRCA1 and BRCA2 81162 Order Options and Pricing
BRIP1 81479,81479
ERCC4 81479,81479
FANCA 81479,81479
FANCB 81479,81479
FANCC 81479,81479
FANCD2 81479,81479
FANCE 81479,81479
FANCF 81479,81479
FANCG 81479,81479
FANCI 81479,81479
FANCL 81479,81479
FANCM 81479,81479
MAD2L2 81479,81479
PALB2 81307,81479
RAD51 81479,81479
RAD51C 81479,81479
RFWD3 81479,81479
SLX4 81479,81479
UBE2T 81479,81479
XRCC2 81479,81479
Test Code Test Copy Genes Panel CPT Code Gene CPT Codes Copy CPT Code Base Price
10361Genes x (22)81479 81162(x1), 81307(x1), 81479(x39) $1380 Order Options and Pricing

Pricing Comments

We are happy to accommodate requests for testing single genes in this panel or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered via our Custom Panel tool.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing backbone).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing backbone).

Turnaround Time

18 days on average for standard orders or 13 days on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.

EMAIL CONTACTS

Genetic Counselors

Geneticist

  • Siwu Peng, PhD

Clinical Features and Genetics of Fanconi Anemia

Clinical Features

Fanconi Anemia (FA) is an inherited disease associated with aberrant DNA repair, an increased risk of bone marrow failure (BMF), hematologic malignancy, and solid tumor development. Many FA patients develop acute myelogenous leukemia (AML), gynecologic or GI tract cancers, or cancers of the head and neck at an earlier age than patients in the general population (Auerbach. 2009. PubMed ID: 19622403). For example, FA patients may be up to 800 fold more susceptible to AML than patients in the general population with a median age of onset of 13 years (Rosenberg et al. 2003. PubMed ID: 12393424). FA affects all systems of the body. While cytopenias due to BMF are the most common presentation of FA, patients may or may not also have additional physical abnormalities and developmental delays, including radial ray defects (absent thumb or radius), skin pigmentation defects, short stature, microphthalmia, renal and urinary tract defects, genital defects (males in particular), gastrointestinal malformations (atresia), congenital heart disease, hearing deficits, and learning difficulties (Tischkowitz and Hodgson. 2003. PubMed ID: 12525534; Dokal. 2000. PubMed ID: 11030042). Up to 79% of FA patients have at least one physical abnormality (Fiesco-Roa et al. 2019. PubMed ID: 31351673) and about 33% of FA patients have three or more features of VACTERL-H (Vertebral, Anal, Cardiac, Tracheo-esophageal fistula, Esophageal atresia, Renal and upper Limb and Hydrocephalus) (Alter and Giri. 2016. PubMed ID: 27028275).

Diagnosis of FA can be complicated as up to one-third of FA patients have no obvious physical or developmental abnormalities and are diagnosed only after a family member is diagnosed, or after developing hematologic complications such as thromobocytopenia, leukopenia, or anemia (Giampietro et al. 1997. PubMed ID: 8986277). A hallmark of FA is hypersensitivity of chromosomes to inter cross-strand linkage (ICL) agents such as diepoxybutane (DEB) or mitomycin C (MMC) (Sasaki and Tonomura. 1973. PubMed ID: 4352739). Exposure of primary cell cultures from FA patients to DEB or MMC results in chromosomal aberrations (breaks, radials, rearrangements) due to damaged DNA repair mechanisms that require functional gene products of the 22 FA genes identified to date.

The FANCA, -B, -C, -E, -F, -G, -L, and -M proteins are part of a nuclear core complex that regulates monoubiquitination of the FANCD2 and FANCI proteins (ID complex) during S-phase and after exposure to DNA crosslinking agents (Moldovan and D'Andrea. 2009. PubMed ID: 19686080). In unaffected individuals, ubiquitination helps localize the ID complex to sites of DNA damage and facilitate repair (Grompe and van de Vrugt. 2007. PubMed ID: 17488615; Smogorzewska et al. 2007. PubMed ID: 17412408), but in FA patients, this mechanism is impaired. Several FA genes are also associated with increased risk of breast cancer including FANCS / BRCA1 (Miki et al. 1994. PubMed ID: 7545954), FANCD1 / BRCA2 (Wooster et al. 1995. PubMed ID: 8524414), FANCJ / BRIP1 (Pennington and Swisher. 2012. PubMed ID: 22264603), FANCN / PALB2 (Walsh and King. 2007. PubMed ID: 17292821), and FANCO / RAD51C (Meindl et al. 2011. PubMed ID: 21637635). FA is phenotypically diverse even among related patients that harbor the same pathogenic variants; null alleles however are reported to result in more severe phenotypes (Faivre et al. 2000. PubMed ID: 11110674). FANCB, -D1, -D2, -I, -J, and –N have been associated with at least one physical abnormality consistently among the literature (over 80% of patients in Fiesco-Roa et al. 2019. PubMed ID: 31351673). FA affects males and females roughly equally and affects all ethnic groups. The range of onset is birth to over 50 years of age, though onset occurs most frequently at younger ages with a median age of onset of 7 years (Shimamura and Alter. 2010. PubMed ID: 20417588; Fiesco-Roa et al. 2019. PubMed ID: 31351673). Given the genotypic and phenotypic heterogeneity found in FA patients, simultaneous genetic testing for a large subset of FA-related genes may provide the most efficient approach for establishing an accurate and timely diagnosis.

In the United States, the carrier frequency for Fanconi anemia is estimated at 1 in 180, and the incidence rate is estimated at 1 in 130,000 (http://www.fanconi.org/; Rosenberg et al. 2011. PubMed ID: 21739583).

Genetics

FA is a genetically heterogeneous disorder. At least 22 genes have been associated with FA or FA-like disorders. Inheritance is primarily autosomal recessive, or with cases of FANCB, X-linked, though a case of heterozygous FA-like syndrome was associated with a dominant-negative variant in the RAD51 (FANCR) gene (Ameziane et al. 2015. PubMed ID: 26681308). Approximately 86% of all FA cases are attributed to variants in one of three genes: FANCA (~ 60%), FANCC (~ 16%), and FANCG (~ 10%) (Auerbach. 2009. PubMed ID: 19622403). Since variants in FANCA are the most common cause of FA, it is important to note that large deletions make up over one-third of all reported pathogenic variants in FANCA. Nearly 95% of all FA cases are attributed to variants in eight genes, FANCA, -C, -G, -D1 (aka BRCA2), -D2, -E, -F, and –L that are either part of the core complex required for ID complex ubiquitination and facilitation of DNA repair, or function directly in ICL recognition and repair (Grompe and van de Vrugt. 2007. PubMed ID: 17488615; Khincha and Savage. 2013. PubMed ID: 24246701). FA is phenotypically diverse even among related patients that harbor common variants; null alleles however are reported to result in more severe phenotypes (Faivre et al. 2000. PubMed ID: 11110674). FANCB, -D1, -D2, -I, -J, and –N have been associated with at least one physical abnormality consistently among the literature (over 80% of patients in Fiesco-Roa et al. 2019. PubMed ID: 31351673). FA affects males and females roughly equally and affects all ethnic groups.

See individual gene summaries for more information about molecular biology of gene products and spectra of pathogenic variants.

Clinical Sensitivity - Sequencing with CNV PGxome

Over 95% of all Fanconi Anemia (FA) patients harbor pathogenic variants in one of the 22 known FA or FA-like genes (www.fanconi.org).

Testing Strategy

This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.

This panel typically provides 98.6% coverage of all coding exons of the genes plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

The homologous region of the FANCD2 gene is covered using Sanger sequencing and PCR primers that distinguish between the FANCD2 gene and the two pseudogenes.

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Patients with clinical features of FA, individuals with a family history of FA, and patients that develop bone marrow failure, hematologic malignancies, or solid tumors at any age, though particularly in young patients.

Genes

Official Gene Symbol OMIM ID
BRCA1 113705
BRCA2 600185
BRIP1 605882
ERCC4 133520
FANCA 607139
FANCB 300515
FANCC 613899
FANCD2 613984
FANCE 613976
FANCF 613897
FANCG 602956
FANCI 611360
FANCL 608111
FANCM 609644
MAD2L2 604094
PALB2 610355
RAD51 179617
RAD51C 602774
RFWD3 614151
SLX4 613278
UBE2T 610538
XRCC2 600375
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Related Test

Name
PGxome®
Congenital Limb Malformation Panel

Citations

  • Alter and Giri. 2016. PubMed ID: 27028275
  • Ameziane et al. 2015. PubMed ID: 26681308
  • Auerbach. 2009. PubMed ID: 19622403
  • Dokal. 2000. PubMed ID: 11030042
  • Faivre et al. 2000. PubMed ID: 11110674
  • Fanconi Anemia Research Fund, Inc.
  • Fiesco-Roa et al. 2019. PubMed ID: 31351673
  • Giampietro et al. 1997. PubMed ID: 8986277
  • Grompe and van de Vrugt. 2007. PubMed ID: 17488615
  • Khincha and Savage. 2013. PubMed ID: 24246701
  • Meindl et al. 2011. PubMed ID: 21637635
  • Miki et al. 1994. PubMed ID: 7545954
  • Moldovan and D'Andrea. 2009. PubMed ID: 19686080
  • Pennington and Swisher. 2012. PubMed ID: 22264603
  • Rosenberg et al. 2003. PubMed ID: 12393424
  • Rosenberg et al. 2011. PubMed ID: 21739583
  • Sasaki and Tonomura. 1973. PubMed ID: 4352739
  • Shimamura and Alter. 2010. PubMed ID: 20417588
  • Smogorzewska et al. 2007. PubMed ID: 17412408
  • Tischkowitz and Hodgson. 2003. PubMed ID: 12525534
  • Walsh and King. 2007. PubMed ID: 17292821
  • Wooster et al. 1995. PubMed ID: 8524414

Ordering/Specimens

Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page


Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×

ORDER OPTIONS

View Ordering Instructions

1) Select Test Method (Backbone)


1) Select Test Type


2) Select Additional Test Options

STAT and Prenatal Test Options are not available with Patient Plus.

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: $
×
Copy Text to Clipboard
×